H U Chengyi1,2, Xiao Lushan2, Zhu Hongbo2,3, Zhang Yanpei2, Zhang Wenfeng4, Liu Li1,2, Zhu Hong5. 1. Department of Medical Quality Management, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. 2. Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. 3. Department of Oncology, The First Affiliated Hospital, University of South China, Hengyang 421001, China. 4. Department of Infectious Diseases, The First Affiliated Hospital, Nanchang University, Nanchang 330006, China. 5. Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Abstract
OBJECTIVE: To determine the impact of hypertension on the outcomes of patients with COVID-19. METHODS: This matched cohort study was conducted among a total 442 patients with COVID-19 admitted in Honghu People's Hospital and First Affiliated Hospital of Nanchang University between January 1 to March 18, 2020, including 61 patients with hypertension and 381 normotensive patients. To minimize the effects of the confounding factors including age, gender and other comorbidities, we excluded patients with comorbidities other than hypertension, and matched the patients with and without hypertension for age and gender at a 1:1 ratio. We analyzed the clinical characteristics, laboratory findings and clinical outcomes of in 32 matched pairs of patients with and without hypertension. RESULTS: Compared with the normotensive patients, COVID-19 patients with hypertension were more likely to develop bacterial infections (P=0.002) and had higher neutrophil counts (P=0.007), neutrophil/lymphocyte ratio (P=0.045), and lactate dehydrogenase levels (P=0.035). A greater proportion of patients had bilateral patchy opacities on chest CT (P=0.012) in the hypertension group than in the normotensive group. COVID-19 patients with hypertension group were more likely to receive antibiotics (P=0.035) and corticosteroid therapies (P=0.035). CONCLUSIONS: Hypertension increases the risk of bacterial infection in patients with COVID-19. Hypertensive patients with COVID-19 have higher neutrophil counts and neutrophil/ lymphocyte ratios and are more likely to require treatment with antibiotics. Hypertensive patients with COVID-19 should therefore take cautions to avoid bacterial infections.
OBJECTIVE: To determine the impact of hypertension on the outcomes of patients with COVID-19. METHODS: This matched cohort study was conducted among a total 442 patients with COVID-19 admitted in Honghu People's Hospital and First Affiliated Hospital of Nanchang University between January 1 to March 18, 2020, including 61 patients with hypertension and 381 normotensive patients. To minimize the effects of the confounding factors including age, gender and other comorbidities, we excluded patients with comorbidities other than hypertension, and matched the patients with and without hypertension for age and gender at a 1:1 ratio. We analyzed the clinical characteristics, laboratory findings and clinical outcomes of in 32 matched pairs of patients with and without hypertension. RESULTS: Compared with the normotensive patients, COVID-19patients with hypertension were more likely to develop bacterial infections (P=0.002) and had higher neutrophil counts (P=0.007), neutrophil/lymphocyte ratio (P=0.045), and lactate dehydrogenase levels (P=0.035). A greater proportion of patients had bilateral patchy opacities on chest CT (P=0.012) in the hypertension group than in the normotensive group. COVID-19patients with hypertension group were more likely to receive antibiotics (P=0.035) and corticosteroid therapies (P=0.035). CONCLUSIONS:Hypertension increases the risk of bacterial infection in patients with COVID-19. Hypertensivepatients with COVID-19 have higher neutrophil counts and neutrophil/ lymphocyte ratios and are more likely to require treatment with antibiotics. Hypertensivepatients with COVID-19 should therefore take cautions to avoid bacterial infections.
Authors: Thomas Unger; Claudio Borghi; Fadi Charchar; Nadia A Khan; Neil R Poulter; Dorairaj Prabhakaran; Agustin Ramirez; Markus Schlaich; George S Stergiou; Maciej Tomaszewski; Richard D Wainford; Bryan Williams; Aletta E Schutte Journal: J Hypertens Date: 2020-06 Impact factor: 4.844
Authors: Sheila K Patel; Elena Velkoska; Melanie Freeman; Bryan Wai; Terase F Lancefield; Louise M Burrell Journal: Front Physiol Date: 2014-06-24 Impact factor: 4.566
Authors: Sara H Al-Hadidi; Hashim Alhussain; Hamad Abdel Hadi; Alreem Johar; Hadi M Yassine; Asmaa A Al Thani; Nahla O Eltai Journal: Microb Drug Resist Date: 2021-06-01 Impact factor: 3.431